Compare NTLA & TH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NTLA | TH |
|---|---|---|
| Founded | 2014 | 1978 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Hotels/Resorts |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.8B |
| IPO Year | 2016 | 2017 |
| Metric | NTLA | TH |
|---|---|---|
| Price | $16.51 | $18.26 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 23 | 2 |
| Target Price | ★ $20.02 | $16.50 |
| AVG Volume (30 Days) | ★ 6.4M | 1.5M |
| Earning Date | 05-07-2026 | 05-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 27.43 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $67,671,000.00 | ★ $320,635,000.00 |
| Revenue This Year | N/A | $17.45 |
| Revenue Next Year | $62.75 | $38.19 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 16.92 | N/A |
| 52 Week Low | $7.95 | $5.97 |
| 52 Week High | $28.24 | $20.85 |
| Indicator | NTLA | TH |
|---|---|---|
| Relative Strength Index (RSI) | 59.46 | 47.78 |
| Support Level | $11.73 | $15.95 |
| Resistance Level | $16.93 | $18.83 |
| Average True Range (ATR) | 1.16 | 0.87 |
| MACD | 0.13 | -0.32 |
| Stochastic Oscillator | 56.30 | 25.51 |
Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.
Target Hospitality Corp is a vertically integrated specialty rental and hospitality services company in the United States. The company provides vertically integrated specialty rental and comprehensive hospitality services, including catering food services, maintenance, housekeeping, grounds-keeping, on-site security, overall workforce lodge management, and laundry service. The company has three reportable segments: HFS - South, which provides specialty rental and hospitality services to the natural resources and development industry; WHS, which provides construction and hospitality solutions for critical mineral and data center projects; and Government, which provides specialty rental and hospitality services under government contracts.